FII-Backed Pharma Stock Reports Outstanding Q2 Results; Announces Fundraising Plans

Sigachi Industries Ltd. announced Q2FY25 and H1FY25 on Wednesday. In the case of Q2FY25, Sigachi Industries earned net revenues of Rs 123.66 crore which is an increase in revenue since Q2FY24 which sat at Rs 80.26 crore. The company had also recorded a significant increase in net profit for the quarter which reached Rs 21.72 crore as opposed to the same period last year when it was Rs 8.37 crore. For the first two quarters of FY25, Sigachi's net revenue was at Rs 205.47 crore compared to Rs 159.73 crore during the last reporting session while net profit increased from Rs 18.51 crore to Rs 31.01 crore during the first two quarters of FY24 respectively. These finances, Syagi stated, show sustained growth through operational management and increased market expansion.

Apart from reporting significant quarterly and half-yearly though earnings, Sigachi Industries has issued a statement telling the public that they would be looking to raise close to USD 100 million by way of Foreign Currency Convertible Bonds or other types of foreign currency instruments.

On the stock market, Sigachi Industries Ltd. shares traded at Rs 51.05 as of Wednesday. Historically, a high of Rs 95.90 and a low of Rs 43.35 puts the stock's 52-week range around that figure giving the company a market capitalization of Rs 1690 crore. Sigachi administered a stock split back in October; this decreased the face value of its equity shares from Rs 10 to Re 10 which on average increased stock access and liquidity in the market.

Recently, the Board of Directors of the Sales offered online on August 30, 2024, granted bail to the equity shareholders who resell them were hammering 52682190 stocks, each accounted for 1 Rs in a post-split issue price of 26.1 per share in the agreement after allowing the conversion of the said warrants. This development is yet another progress in the quest of the company ensuring increased equity for its future requirements.

In line with its mandate of broadening its products, the Company has announced the introduction of its new drug delivery technology, PureCoat and UltraMod which will change the way drugs are delivered. The new film coatings and polymer blends will improve the stability and bioavailability of drugs which are vital areas in the pharmaceutical industry.

Projected to reach 1.62 billion US dollars by 2031, Sigachi focuses on capturing 16-18 per cent market share within India which has around 15 per cent contribution to the overall market for pharmaceutical coatings.

The company is listed on the NSE and BSE stock exchanges and operates five advanced manufacturing plants located in Telangana, Gujarat, and Karnataka and has subsidiaries in the US and UAE. Sigachi's multifaceted portfolio, which includes excipients, APIs, and custom nutrient blends, has clientele in 62 countries supported by quality and consistency certification through international institutions.